U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299747) titled 'Phase I/IIa Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors' on Dec. 09.
Brief Summary: This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.
Study Start Date: Dec. 04
Study Type: INTERVENTIONAL
Condition:
Participants With Advanced Solid Tumor Malignancies
Intervention:
DRUG: VBC103
VBC103
Recruitment Status: RECRUITING
Sponsor: VelaVigo Bio Inc
Published by HT Digital Content Services w...